Reason for request
Inclusion on the list of medicines approved for use by hospitals in the new indication: “treatment of multifocal motor neuropathy (MMN)”.
Clinical Benefit
| Substantial |
The actual benefit provided by TEGELINE in this indication is substantial. |
Clinical Added Value
| important |
The Transparency Committee considers that TEGELINE provides a substantial improvement in actual benefit (IAB II) in patients with multifocal motor neuropathy. |
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
aLHw3DyynYcfnxjW
